MX2019007826A - Activador nrf2. - Google Patents
Activador nrf2.Info
- Publication number
- MX2019007826A MX2019007826A MX2019007826A MX2019007826A MX2019007826A MX 2019007826 A MX2019007826 A MX 2019007826A MX 2019007826 A MX2019007826 A MX 2019007826A MX 2019007826 A MX2019007826 A MX 2019007826A MX 2019007826 A MX2019007826 A MX 2019007826A
- Authority
- MX
- Mexico
- Prior art keywords
- nrf2 activator
- nrf2
- activator
- compounds
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/08—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with a hetero atom directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
- C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/76—Benzo[c]pyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan compuestos de formula I, o las sales farmaceuticamente aceptables de estos, y metodos para su uso y produccion.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662439289P | 2016-12-27 | 2016-12-27 | |
PCT/US2017/068455 WO2018125880A1 (en) | 2016-12-27 | 2017-12-27 | Nrf2 activator |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019007826A true MX2019007826A (es) | 2019-10-24 |
Family
ID=61007836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019007826A MX2019007826A (es) | 2016-12-27 | 2017-12-27 | Activador nrf2. |
Country Status (21)
Country | Link |
---|---|
US (2) | US10968181B2 (es) |
EP (2) | EP3562816B1 (es) |
JP (1) | JP7088933B2 (es) |
KR (1) | KR20190111949A (es) |
CN (1) | CN110382475A (es) |
AR (1) | AR110590A1 (es) |
AU (1) | AU2017387070B2 (es) |
BR (1) | BR112019013341A2 (es) |
CA (1) | CA3048849A1 (es) |
CL (1) | CL2019001804A1 (es) |
CO (1) | CO2019008110A2 (es) |
CR (1) | CR20190344A (es) |
EA (1) | EA201991595A1 (es) |
ES (1) | ES2878102T3 (es) |
IL (1) | IL267692B (es) |
JO (1) | JOP20190163B1 (es) |
MX (1) | MX2019007826A (es) |
PE (1) | PE20191488A1 (es) |
TW (1) | TW201827406A (es) |
UY (1) | UY37551A (es) |
WO (1) | WO2018125880A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS64836B1 (sr) * | 2018-10-22 | 2023-12-29 | C4X Discovery Ltd | Terapijska jedinjenja |
JP2022510736A (ja) | 2018-12-05 | 2022-01-27 | 株式会社スコヒアファーマ | 大環状化合物とその使用 |
CN112679328B (zh) * | 2019-10-17 | 2023-09-15 | 南京药石科技股份有限公司 | 一种3-三氟甲基-2-环己烯-1-酮的工业化生产方法 |
KR102664144B1 (ko) | 2021-08-05 | 2024-05-10 | 주식회사 엘씨에스바이오텍 | 신규한 곡류 발효물, 그 곡류 발효물의 피부 보호 용도, 피부 유용 물질 스크리닝 방법 및 산화적 스트레스로 인한 피부 손상 예측 방법 |
WO2024091523A1 (en) * | 2022-10-24 | 2024-05-02 | 2A Biosciences, Inc. | Conformationally restricted phenethylamine analogs |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
JP2008110962A (ja) * | 2006-08-02 | 2008-05-15 | Santen Pharmaceut Co Ltd | Nrf2活性化物質を有効成分として含む角結膜障害の予防または治療剤 |
BRPI0911105B1 (pt) * | 2008-04-18 | 2022-11-08 | Reata Pharmaceuticals, Inc | Compostos contendo um farmacóforo anti-inflamatório, composição farmacêutica, bem como seus usos |
US9139592B2 (en) * | 2010-06-14 | 2015-09-22 | Trt Pharma Inc. | Modulators of Nrf2 and uses thereof |
EP2678305A4 (en) * | 2011-02-25 | 2015-11-04 | Univ Johns Hopkins | CHALCONE DERIVATIVES AS NRF2 ACTIVATORS |
EP3209658A1 (en) * | 2014-10-24 | 2017-08-30 | Biogen MA Inc. | Diterpenoid derivatives and methods of use thereof |
WO2016203400A1 (en) * | 2015-06-15 | 2016-12-22 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
-
2017
- 2017-12-26 AR ARP170103684A patent/AR110590A1/es unknown
- 2017-12-26 UY UY0001037551A patent/UY37551A/es unknown
- 2017-12-27 ES ES17832681T patent/ES2878102T3/es active Active
- 2017-12-27 CR CR20190344A patent/CR20190344A/es unknown
- 2017-12-27 PE PE2019001341A patent/PE20191488A1/es unknown
- 2017-12-27 EA EA201991595A patent/EA201991595A1/ru unknown
- 2017-12-27 MX MX2019007826A patent/MX2019007826A/es unknown
- 2017-12-27 CN CN201780087398.9A patent/CN110382475A/zh active Pending
- 2017-12-27 JP JP2019535363A patent/JP7088933B2/ja active Active
- 2017-12-27 TW TW106146033A patent/TW201827406A/zh unknown
- 2017-12-27 AU AU2017387070A patent/AU2017387070B2/en not_active Ceased
- 2017-12-27 BR BR112019013341A patent/BR112019013341A2/pt active Search and Examination
- 2017-12-27 EP EP17832681.5A patent/EP3562816B1/en active Active
- 2017-12-27 US US16/473,667 patent/US10968181B2/en active Active
- 2017-12-27 KR KR1020197022052A patent/KR20190111949A/ko not_active Application Discontinuation
- 2017-12-27 WO PCT/US2017/068455 patent/WO2018125880A1/en active Application Filing
- 2017-12-27 JO JOP/2019/0163A patent/JOP20190163B1/ar active
- 2017-12-27 CA CA3048849A patent/CA3048849A1/en active Pending
- 2017-12-27 EP EP21152411.1A patent/EP3875450A1/en not_active Withdrawn
-
2019
- 2019-06-27 CL CL2019001804A patent/CL2019001804A1/es unknown
- 2019-06-27 IL IL267692A patent/IL267692B/en unknown
- 2019-07-26 CO CONC2019/0008110A patent/CO2019008110A2/es unknown
-
2021
- 2021-04-02 US US17/221,358 patent/US20210340107A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL267692B (en) | 2021-09-30 |
WO2018125880A8 (en) | 2019-06-06 |
US10968181B2 (en) | 2021-04-06 |
BR112019013341A2 (pt) | 2019-12-24 |
JP7088933B2 (ja) | 2022-06-21 |
PE20191488A1 (es) | 2019-10-21 |
JOP20190163A1 (ar) | 2019-06-27 |
ES2878102T3 (es) | 2021-11-18 |
US20190345112A1 (en) | 2019-11-14 |
AU2017387070A1 (en) | 2019-08-15 |
US20210340107A1 (en) | 2021-11-04 |
EP3875450A1 (en) | 2021-09-08 |
JP2020503332A (ja) | 2020-01-30 |
CA3048849A1 (en) | 2018-07-05 |
UY37551A (es) | 2018-07-31 |
IL267692A (en) | 2019-08-29 |
JOP20190163B1 (ar) | 2023-09-17 |
EA201991595A1 (ru) | 2020-01-27 |
AR110590A1 (es) | 2019-04-10 |
CN110382475A (zh) | 2019-10-25 |
CL2019001804A1 (es) | 2019-11-15 |
TW201827406A (zh) | 2018-08-01 |
AU2017387070B2 (en) | 2022-03-24 |
KR20190111949A (ko) | 2019-10-02 |
WO2018125880A1 (en) | 2018-07-05 |
CO2019008110A2 (es) | 2019-08-20 |
EP3562816A1 (en) | 2019-11-06 |
EP3562816B1 (en) | 2021-01-20 |
CR20190344A (es) | 2019-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW201613872A (en) | IRAK4 inhibiting agents | |
PH12016501972B1 (en) | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors | |
MX2016015862A (es) | Compuestos inhibidores de la cinasa de union a tank. | |
MD20170016A2 (ro) | Compuşi aminopirimidinici ca inhibitori JAK | |
MX2017006266A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos. | |
MA39749A (fr) | Dérivés de pipéridine-dione | |
MA40171A (fr) | Dérivés d'azamophinan et leur utilisation | |
JOP20190163B1 (ar) | منشط nrf2 | |
MX2016015565A (es) | Ciertos inhibidores de la proteina quinasa. | |
PH12019501639A1 (en) | Jaki selective inhibitors | |
EA201790627A1 (ru) | СТИМУЛЯТОРЫ рГЦ | |
TW201613864A (en) | Novel compounds | |
PH12017500459A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
MY186475A (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder | |
EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы | |
AU2017257755A1 (en) | Benzoylglycine derivatives and methods of making and using same | |
MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
EA033423B1 (ru) | Циклопропанбензофуранилпиридопиразиндионы | |
EA201791099A1 (ru) | Хинолин карбоксамиды для применения в лечении лейкоза | |
MX2016010877A (es) | Amidas antimitoticas para el tratamiento del cancer y desordenes proliferativos. | |
MX2020005707A (es) | Profarmacos de creatina, composiciones y metodos de uso de estos. | |
WO2018075598A8 (en) | SYNTHESIS OF EZH2 INHIBITORS | |
MX2019005723A (es) | Inhibidor del receptor del factor de crecimiento de fibroblastos 4 (fgfr4) y metodo de preparacion y uso del mismo. | |
PH12016502480A1 (en) | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | |
MX2019005504A (es) | Potenciadores de bmp. |